http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
다공성 물질에 부착한 토양미생물에 의한 유기성 폐수처리에 관한 실험적 연구
정연규,홍승모,박준환 연세대학교 산업기술연구소 1991 논문집 Vol.23 No.1
In this research, Briquette Ashes, one of the important solid wastes in Korea, were used as media in a fixed-film biological process to evaluate the efficiency of organic wasterwater treatment by soil microbes attached to porous media and adsorption capacity of Briquette Ashes in the reactors. As the result, hydraulic retention time and aeration rate for optimum operation were 24 hours, 5ℓ/min in the reactors seeded with microbes. And the adsorption capacity of Briquette Ashes came to get maximum removal efficiency when it was controlled to (24 hours, 4ℓ/min), but removal efficiency was decreased with time. In addition, the organic removal efficiencies were 93.4, 90.8% under these operating conditions respectively. Particularly, NH₃-N efficiency was about 85%, the average value of F/M ratio was 0.15g COD/g VS-day. Setting characteristics of sludge were good, for SVI was 23.6 in the seeding reactors.
Comparison of the Antibacterial Properties of Phage Endolysins SAL-1 and LysK
Jun, Soo Youn,Jung, Gi Mo,Son, Jee-Soo,Yoon, Seong Jun,Choi, Yun-Jaie,Kang, Sang Hyeon American Society for Microbiology 2011 Antimicrobial Agents and Chemotherapy Vol.55 No.4
<B>ABSTRACT</B><P>In spite of the high degree of amino acid sequence similarity between the newly discovered phage endolysin SAL-1 and the phage endolysin LysK, SAL-1 has an approximately 2-fold-lower MIC against several<I>Staphylococcus aureus</I>strains and higher bacterial cell-wall-hydrolyzing activity than LysK. The amino acid residue change contributing the most to this enhanced enzymatic activity is a change from glutamic acid to glutamine at the 114th residue.</P>
Jun, Soo Youn,Jung, Gi Mo,Yoon, Seong Jun,Choi, Yun-Jaie,Koh, Woo Suk,Moon, Kyoung Sik,Kang, Sang Hyeon American Society for Microbiology 2014 Antimicrobial Agents and Chemotherapy Vol.58 No.4
<P>Phage endolysins have received increasing attention as potent antibacterial agents. However, although safety evaluation is a prerequisite for the drug development process, a good laboratory practice (GLP)-compliant safety evaluation has not been reported for phage endolysins. A safety evaluation of intravenously administered SAL200 (containing phage endolysin SAL-1) was conducted according to GLP standards. No animals died in any of the safety evaluation studies. In general toxicity studies, intravenously administered SAL200 showed no sign of toxicity in rodent single- and repeated-dose toxicity studies. In the dog repeated-dose toxicity test, there were no abnormal findings, with the exception of transient abnormal clinical signs that were observed in some dogs when daily injection of SAL200 was continued for more than 1 week. In safety pharmacology studies, there were also no signs of toxicity in the central nervous and respiratory system function tests. In the cardiovascular function test, there were no abnormal findings in all tested dogs after the first and second administrations, but transient abnormalities were observed after the third and fourth administrations (2 or 3 weeks after the initial administration). All abnormal findings observed in these safety evaluation studies were slight to mild, were apparent only transiently after injection, and resolved quickly. The safety evaluation results for SAL200 support the implementation of an exploratory phase I clinical trial and underscore the potential of SAL200 as a new drug. We have designed an appropriate phase I clinical trial based on the results of this study.</P>
Jun, Soo Youn,Jang, In Jin,Yoon, Seonghae,Jang, Kyungho,Yu, Kyung-Sang,Cho, Joo Youn,Seong, Moon-Woo,Jung, Gi Mo,Yoon, Seong Jun,Kang, Sang Hyeon American Society for Microbiology 2017 Antimicrobial Agents and Chemotherapy Vol.61 No.6
<P><B>ABSTRACT</B></P><P>This study was a phase 1, single-center, randomized, double-blind, placebo-controlled, single-dosing, and dose-escalating study of intravenous SAL200. It is a new candidate drug for the treatment of antibiotic-resistant staphylococcal infections based on a recombinant form of the phage endolysin SAL-1. The study evaluated the pharmacokinetics, pharmacodynamics, and tolerance among healthy male volunteers after the intravenous infusion of single ascending doses of SAL200 (0.1, 0.3, 1, 3, and 10 mg/kg of body weight). SAL200 was well tolerated, and no serious adverse events (AEs) were observed in this clinical study. Most AEs were mild, self-limiting, and transient. The AEs reported in more than three participants were fatigue, rigors, headache, and myalgia. No clinically significant values with respect to the findings of clinical chemistry, hematology, and coagulation analyses, urinalysis, vital signs, and physical examinations were observed, and no notable trends in our electrocardiogram (ECG) results for any tested dose were noticed. A greater-than-dose-proportional increase with regard to systemic exposure and the maximum serum concentration was observed when the SAL200 dose was increased from 0.1 mg/kg to 10 mg/kg. This investigation constitutes the first-in-human phase 1 study of an intravenously administered, phage endolysin-based drug. (This study has been registered at ClinicalTrials.gov under identifier NCT01855048 and at the Clinical Research Information Service [https://cris.nih.go.kr/cris/] under identifier KCT0000968.).</P>
김준환 ( Jun Hwan Kim ),오승환 ( Seung Hwan Oh ),전지영 ( Ji-young Jun ),심준호 ( Joon Ho Shim ),박지혜 ( Ji-hye Park ),이종희 ( Jong Hee Lee ),이동윤 ( Dong-youn Lee ),이주흥 ( Joo-heung Lee ),양준모 ( Jun-mo Yang ) 대한피부과학회 2016 대한피부과학회지 Vol.54 No.3
Cryotherapy is a simple, relatively inexpensive therapeutic modality that is widely-used in clinical practice. It is especially appropriate for patients with an intolerance to anesthesia as well as high risk factors for developing hypertrophic scars after surgery. It can be applied to skin lesions located close to vital structures such as vessels and nerves. Potential side effects include pain, hemorrhage, edema, blisters, infection, hypopigmentation, and sensory damage. There are a numerous reports in the literature describing the side effects of cryotherapy. However, cases with severe complications have rarely been reported as yet. Herein, we report a case of serious complications of cryotherapy, a result of the course of treatment for linear porokeratosis. (Korean J Dermatol 2016;54(3):203~205)
Efficacy of K-D wire and factors that influence the outcome of the device
( Ji Young Jun ),( Seung Hwan Oh ),( Joon Ho Shim ),( Jun Hwan Kim ),( Ji Hye Park ),( Jong Hee Lee ),( Dong Youn Lee ),( Joo Heung Lee ),( Jun Mo Yang ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.2
Background: Ingrown nail is a common nail disorder frequently resulting pain and disabilities in daily life. It is often difficult to manage despite the multitude oftreatment modalities. K-D wire三 is a recently developed device with shape-memory alloy for treatment of ingrown nail. Objectives: The aim of this study was to evaluate the recurrence rate of K-D wire三 and to determine what factors influence the outcome of the device.Methods: Between June 2010 and July 2015, 86 nails of 62 patients underwent K-D wire insertion in departmentof dermatology of Samsung Medical Center, Seoul. Removal of device and follow up was done for 56 nails. Mean age of affected patients, average stage of ingrown nails, application period of K-D wire, history ofonychomycosis, presence of subungual hyperkeratosis, nail plate width, curvature, center-to-edge angle, and type of ingrown nail was assessed for all nails and compared them between recur group and non-recur group. Results: Recurrence rate was 21.4%. Application period was signifiacant lower in recur group. Other factors were not significantly different from recur to non-recur group. Conclusion: Low recurrence rate was associated with at least 4 weeks of application of K-D wire. Other factors were not associated with recurrence. Since spontaneous dislocation is frequent in K-D wire insertion, developing strategies to reduce early dislocation is important for better efficacy of the device.
D-dimer level in chronic urticaria patients
( Ji Young Jun ),( Seung Hwan Oh ),( Joon Ho Shim ),( Jun Hwan Kim ),( Ji Hye Park ),( Jong Hee Lee ),( Dong Youn Lee ),( Joo Heung Lee ),( Jun Mo Yang ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.2
Background: Chronic urticaria is a common disorder affecting 1% of population. The pathophysiology of chronic urticaria is not clearly known but the role of extrinsic coagulation pathway is thought to be suggestiverecently. D-dimer is a degradation product by fibrinolysis and activation of coagulation pathway elevates D-dimer. There are controversial studies suggesting role of D-dimer in urticaria patients. Objectives: The aim of this study is to compare D-dimer level in chronic urticaria and acute urticaria patients and evaluate association between D-dimer level and response to antihistamine in chronic urticaria and the change in response to antihistamine after normalization of D-dimer by tranexamic acid. Methods: We retrospectively reviewed patients who were diagnosed as urticaria and checked D-dimer level in department of dermatology, Samsung Medical Center, Seoul, from 2010 to 2014. Results: 716 chronic urticaria patients and 36 acute urticaria pateints were included and average D-dimer level was 0.45 and 1.49 respectively. Propertion of D-dimer elevated patient was 21.1% and 41.7% respectively. D-dimer level was significantly high in antihistamine poor responders than good to partial responders, but theproportion of D-dimer elevated patient was notsignificant. After D-dimer normalization with tranexamic acid, 42.4% of antihistamine poor responders showed better response. Conclusion: D-dimer may be a biomarker for anti- histamine resistant chronic urticaria.
FCT 11 : Efficacy of laser therapy in early postoperative thyroidectomy scar
( Jun Hwan Kim ),( Joon Ho Shim ),( Se Won Park ),( Hyun Tae Shin ),( Ji Ho Park ),( Jong Hee Lee ),( Dong Youn Lee ),( Joo Heung Lee ),( Jun Mo Yang ) 대한피부과학회 2013 대한피부과학회 학술발표대회집 Vol.65 No.2
Background: Interest in surgical scars is on the rise with increasing frequency of surgical procedures. The site of thyroidectomy is the anterior neck, which is also a prominently exposed part of the body, where postoperative scarring can cause patients` distress. Various types of lasers are effectively used to improve the appearance of scars but optimal treatment time has not been established. Objectives: To evaluate the efficacy and safety of laser therapy in early postoperative thyroidectomy scars. Methods: We reviewed the medical records of 43 thyroidectomy patients who were divided into two groups based on treatment time. Early treatment group started laser therapy within the first month and late treatment group at least 1 month after the thyroidectomy. Each group was treated with 595nm Pulse dye and fractional laser till achieving cosmetic acceptable outcome (Delta VSS score > 4). We used the Vancouver Scar Scale (VSS). Evaluations were performed based on medical photograph which was taken before each treatment. Results: Mean VSS scores were statistically significantly lower after laser treatment (P<0.01).Early treatment group require fewer treatment sessions and less expense than Late treatment group (P<0.01). Conclusion: Using lasers as prophylaxis against scarring would require fewer treatment sessions and less expense than using lasers to treat mature scars.
( Jun Hwan Kim ),( Hae Young Park ),( Jong Hee Lee ),( Dong Youn Lee ),( Joo Heung Lee ),( Jun Mo Yang ) 대한피부과학회 2015 Annals of Dermatology Vol.27 No.6
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN), which is derived from the precursor of plasmacytoid dendritic cells, is a rare and highly aggressive hematologic malignancy. It has only recently been recognized as a distinct entity. BPDCN characteristically has a predilection for cutaneous involvement. Objective: The aim of this study was to describe the clinical and pathological features of BPDCN, and to review the treatment courses to analyze the prognosis and the optimal therapeutic approach. Methods: We retrospectively reviewed seven BPDCN cases registered in the Samsung Medical Center database between January 2010 and December 2014. Results: The median age of the patients was 52 years (range, 18∼79 years), and six patients were male. The clinical staging was as follows: skin (n=5), lymph node (n=6), bone marrow (n=4), and peripheral blood (n=2). The skin manifestations were bruise-like tumefaction (n=4), erythematous nodule (n=4), or multiple erythematous papules (n=1). The pathological evaluation revealed dense diffuse or nodular infiltration of neoplastic cells, which were positive for CD4, CD56, and CD123 in the immunohistochemical analysis. Six patients received multiagent chemotherapy as the first-line treatment, alone (n=4), or followed by stem cell transplantation (SCT, n=1) or concurrent radiotherapy (n=1). The median progression-free survival after the first-line treatment was 6 months (range, 2 ∼12 months). Conclusion: Three different skin manifestations were observed, with pathological features analogous to each other. All patients who received chemotherapy without SCT achieved partial or complete response but experienced relapse. Furthermore, they showed various clinical courses irrelevant to the cutaneous involvement. (Ann Dermatol 27(6) 727∼737, 2015)